Advisory Research’s Oak Street Health, Inc. OSH Stock Holding History

Advisory Research’s Portfolio OSH Stock Details OSH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,730	Closed	-$252K	–	423
2022 Q4	$252K	Buy	11,730 +3,514	+43%	+$73.5K	0.02%	316
2022 Q3	$201K	Buy	+8,216	New	+$217K	0.02%	310

Other funds holding OSH

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Advisory Research's OSH Position: Q1 2023 in Review

Advisory Research sold out of Oak Street Health, Inc. (OSH) in Q1 2023, closing a stake of 11,730 shares — an estimated $252K sold.

Advisory Research first reported a position in OSH in Q3 2022 and held it in 2 quarters. The position peaked at $252K in Q4 2022. 272 funds tracked by Wall St. Rank hold OSH as of Q1 2023.

Advisory Research reported no remaining Oak Street Health, Inc. position as of Q1 2023 after selling out during the quarter.
Advisory Research sold 11,730 Oak Street Health, Inc. shares in Q1 2023, an estimated $252K.
Advisory Research first reported a position in Oak Street Health, Inc. in Q3 2022 and held it in 2 quarters.
Advisory Research's Oak Street Health, Inc. position peaked at $252K in Q4 2022.
272 funds tracked by Wall St. Rank held Oak Street Health, Inc. as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.